And

are now a part of the new and improved

search Created with Sketch.
search Created with Sketch.

Advertisement

Topic: Eczema

Updates on AD Therapeutics thumbnail
Play Button

Updates on AD Therapeutics

Series: Dermatology Dispatches | April 2, 2020

It's a "super-exciting" time in the world of atopic dermatitis because of a number of new developments happening very rapidly, shares Peter Lio, MD. Recent approvals and additional indications for treatments like dupilumab and crisaborole in pediatric populations have been welcome additions. And there are biologics—IL-13 and IL-31 inhibitors—and JAK inhibitors in the pipeline showing promise.

Watch Video
Advances in Treating Pediatric Inflammatory Skin Diseases thumbnail
Play Button

Advances in Treating Pediatric Inflammatory Skin Diseases

Series: Maui Derm for Dermatologists 2020 | February 12, 2020

From new treatment guidelines to emerging biologic therapies for psoriasis in pediatric patients, Lawrence Eichenfield, MD says there’s new hope in successfully treating this patient population. He also discusses advances in treating pediatric atopic dermatitis. 

Watch Video
Updates in Pediatric Dermatology thumbnail
Play Button

Updates in Pediatric Dermatology

Series: Maui Derm for Dermatologists 2020 | January 28, 2020

2019 was bookended by the release of new treatment guidelines for pediatric skin disorders. Sheila Fallon Friedlander, MD, gives an overview of these developments and other hot topics in pediatric dermatology.

Watch Video
DermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates thumbnail
Play Button

DermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates

Series: DermWire TV | January 21, 2020

On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine. A fourth product, RHA 1, is currently in clinical trials in the US with FDA approval anticipated in 2021. Almirall seeks to enhance its early-stage research portfolio and expand its medical dermatology pipeline with three new collaborations.

Watch Video
DermWireTV: Cosmetic Surgery Forum Highlights, LEO Focuses on AD thumbnail
Play Button

DermWireTV: Cosmetic Surgery Forum Highlights, LEO Focuses on AD

Series: DermWire TV | December 12, 2019

New treatments and medical controversies take center stage at Cosmetic Surgery Forum as the meeting moves to Nashville in its 11th Year. Leo Pharma’s tralokinumab meets all primary and secondary endpoints in three pivotal Phase 3 studies for the treatment of adults with moderate-to-severe atopic dermatitis.

Watch Video

Advertisement

The Latest in Eczema

Advertisement

View more